Olema Announces New Data from Palazestrant Cancer Trial
Median PFS reached 15.5 months in the 120 mg palazestrant cohort across all comers, with 12.2 months among patients...
eClinical Tech News
Disc Medicine Presents New Phase 1b CKD/Anemia Trial Data
Disc Medicine will deliver a full Phase 1b update of DISC-0974 in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients with...
AI Cancer Vaccine Shows Surging 75% Response in Phase 2 Trial
Evaxion reported a 75% objective response rate in a 16-patient Phase 2 study of EVX-01 plus pembrolizumab in first-line...
FDA Approves Junshi’s New Phase 2/3 NSCLC Clinical Study
Junshi Biosciences has received FDA IND clearance to initiate an international, open-label, randomized phase 2/3 study testing its PD-1/VEGF...
ANI Pharma to Present New Day Clinical Trial Data at AAO 2025
No new efficacy or safety figures were disclosed in today’s announcement, but ANI Pharmaceuticals will showcase the already reported...
Anteris Gets First EU Clearance for DuraVR Pivotal Trial
The PARADIGM pivotal trial will randomize approximately 1,000 “all-comer” patients with severe calcific aortic stenosis 1:1 to the DurAVR...
Artelo to Present Expanded Clinical Data at Cannabinoid Summit
Patients in Artelo’s CAReS Phase 2 trial of ART27.13, a once-daily dual cannabinoid agonist for cancer-related anorexia, gained an...
Aprea Sets Phase 2 Dose for ATRN-119 Combination Therapy
Aprea set the monotherapy recommended Phase 2 dose for ATRN-119, its oral ATR inhibitor, at 1,100 mg once daily...
First Patient Enrolled for Prostate Cancer Trial in Japan
Curium’s global Phase 3 ECLIPSE trial of 177Lu-PSMA-I&T met its primary endpoint with statistically significant, clinically meaningful benefit in...
Surging Lung Cancer ADC Market: FDA Trials & Opportunity
Global lung cancer ADCs have moved from niche to scale: the new Kuick Research analysis pegs 2024 revenue at...